ATE301462T1 - Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden - Google Patents

Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden

Info

Publication number
ATE301462T1
ATE301462T1 AT99916114T AT99916114T ATE301462T1 AT E301462 T1 ATE301462 T1 AT E301462T1 AT 99916114 T AT99916114 T AT 99916114T AT 99916114 T AT99916114 T AT 99916114T AT E301462 T1 ATE301462 T1 AT E301462T1
Authority
AT
Austria
Prior art keywords
disorders
reboxetine
addiction
neuropsychiatric conditions
treat neuropsychiatric
Prior art date
Application number
AT99916114T
Other languages
English (en)
Inventor
Fred Hassan
John Michael Mccall
Duncan Paul Taylor
Voigtlander Philip F Von
Erik Ho Fong Wong
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of ATE301462T1 publication Critical patent/ATE301462T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT99916114T 1998-04-09 1999-04-02 Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden ATE301462T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8123198P 1998-04-09 1998-04-09
PCT/US1999/004289 WO1999052531A1 (en) 1998-04-09 1999-04-02 New treatments for nervous disorders

Publications (1)

Publication Number Publication Date
ATE301462T1 true ATE301462T1 (de) 2005-08-15

Family

ID=22162900

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99916114T ATE301462T1 (de) 1998-04-09 1999-04-02 Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden

Country Status (24)

Country Link
US (1) US6352986B1 (de)
EP (1) EP1069900B1 (de)
JP (1) JP2002511414A (de)
KR (1) KR20010034758A (de)
CN (1) CN1301164A (de)
AT (1) ATE301462T1 (de)
AU (1) AU756373B2 (de)
BR (1) BR9909478A (de)
CA (2) CA2321157A1 (de)
CZ (1) CZ297346B6 (de)
DE (1) DE69926616T2 (de)
DK (1) DK1069900T3 (de)
EA (1) EA200001049A1 (de)
ES (1) ES2244189T3 (de)
HU (1) HUP0102436A3 (de)
IL (1) IL138855A0 (de)
NO (1) NO20005059D0 (de)
NZ (1) NZ507398A (de)
PL (1) PL193797B1 (de)
PT (1) PT1069900E (de)
SK (1) SK14492000A3 (de)
TR (1) TR200002868T2 (de)
WO (1) WO1999052531A1 (de)
ZA (1) ZA200004454B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
EP1500395B1 (de) * 1999-07-01 2006-03-08 Pharmacia & Upjohn Company LLC Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
CN1660108A (zh) * 1999-07-01 2005-08-31 法玛西雅厄普约翰美国公司 高度选择性去甲肾上腺素再摄取抑制剂及其用途
BR0108980A (pt) * 2000-03-07 2003-06-03 Lilly Co Eli Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
JP4708795B2 (ja) 2002-12-20 2011-06-22 ニコノヴァム エービー 物理的および化学的に安定なニコチン−含有粒状物質
KR20080044840A (ko) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
WO2012024397A2 (en) 2010-08-17 2012-02-23 Albany Molecular Research, Inc. 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
DE3275000D1 (en) * 1981-08-07 1987-02-12 Holset Engineering Co Impeller for centrifugal compressor
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
EA000856B1 (ru) * 1995-07-24 2000-06-26 Эли Лилли Энд Компани Способ лечения синдрома дефицита внимания/гиперактивности
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки

Also Published As

Publication number Publication date
BR9909478A (pt) 2000-12-19
DK1069900T3 (da) 2005-10-31
JP2002511414A (ja) 2002-04-16
AU3449499A (en) 1999-11-01
EP1069900A1 (de) 2001-01-24
DE69926616T2 (de) 2006-05-24
WO1999052531A1 (en) 1999-10-21
CZ20003671A3 (en) 2001-06-13
DE69926616D1 (de) 2005-09-15
EP1069900B1 (de) 2005-08-10
SK14492000A3 (sk) 2001-06-11
PT1069900E (pt) 2005-10-31
CN1301164A (zh) 2001-06-27
CA2321157A1 (en) 1999-10-21
PL346293A1 (en) 2002-01-28
KR20010034758A (ko) 2001-04-25
PL193797B1 (pl) 2007-03-30
EA200001049A1 (ru) 2001-04-23
IL138855A0 (en) 2001-10-31
NZ507398A (en) 2004-01-30
HUP0102436A2 (hu) 2001-11-28
HUP0102436A3 (en) 2002-01-28
TR200002868T2 (tr) 2001-01-22
AU756373B2 (en) 2003-01-09
ES2244189T3 (es) 2005-12-01
NO20005059L (no) 2000-10-06
ZA200004454B (en) 2002-04-24
CA2634698A1 (en) 1999-10-21
US6352986B1 (en) 2002-03-05
CZ297346B6 (cs) 2006-11-15
NO20005059D0 (no) 2000-10-06

Similar Documents

Publication Publication Date Title
MY127739A (en) Use of pramipexole for the treatment of addictive disorders
ATE301462T1 (de) Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
TW200607510A (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE69305776D1 (de) Behandlung neurodegenerativer Krankheiten
DK0796103T3 (da) Anvendelse af røgelse til behandling af Alzheimer-sygdommen
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
NO20023486L (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
ATE296098T1 (de) Verwendung von topiramat zur behandlung und diagnostizierung von atemstörungen während des schlafens und mittel zur durchführung der behandlung und diagnose
DE3685853D1 (de) Mittel zur behandlung von knochenkrankheiten.
BR9506748A (pt) Compostos preparação farmacêutica utilização de um composto e processos para o tratamento de um indivíduo sofrendo de dor e para a preparação de um composto
EA200300271A1 (ru) Соединения для лечения расстройств, связанных с зависимостью
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
EA200001058A1 (ru) Новые способы лечения нервных расстройств
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
DE69910242D1 (de) Verwendung eines Nikotin-Rezeptor Agonisten zur Herstellung eines Medikaments zur Behandlung von Zwangsneurosen
FR2801790B1 (fr) Association retinal et aldehydes, composition cosmetique la contenant, a titre de medicament l'association retinal et aldehydes, et procede de preparation de cette association
DE60003921D1 (de) Diphenyl-1,2,3-thiadiazol-3-oxide, zusammensetzungen und verfahren zur anwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1069900

Country of ref document: EP

REN Ceased due to non-payment of the annual fee